Compare Costco Wholesale Corporation (COST) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Costco Wholesale Corporation vs Mesoblast Limited — how do they compare? Costco Wholesale Corporation trades at $943.45 (market cap $418.79B), while Mesoblast Limited trades at $16.68 (market cap $2.21B). The key difference: Costco Wholesale Corporation is far larger — about 189.5× Mesoblast Limited's market cap, and Costco Wholesale Corporation pays a 0.62% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| COST | MESO | |
|---|---|---|
Market Cap | $418.79B | $2.21B |
Sector | Consumer Staples | Technology |
52-Week High | $1.09K | $20.96 |
52-Week Low | $849.63 | $12.88 |
Enterprise Value | $406.93B | $2.21B |
Dividend Yield | 0.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Costco (COST) trades at $952.75, up 0.52% with a neutral technical outlook. The stock shows strong fundamentals with revenue growth from $254.5B in 2024 to $275.2B in 2025 and net income reaching $8.1B. Recent March sales surged 11.3% year-over-year to $28.41B. Valuation metrics remain elevated with P/E at 47.93 and P/S at 1.44. Analyst consensus is strongly bullish with 65.5% buy ratings and a $1,120 price target.
The investment case centers on Costco's membership-driven profit engine and consistent execution, though high valuation presents near-term risk. Upside potential exists if the company maintains its premium growth trajectory, while any earnings disappointment could trigger valuation compression. The recent membership fee increase and strong renewal rates support margin expansion prospects.
MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.
Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Costco Wholesale Corporation
The leading warehouse club, Costco has 815 stores worldwide (at the end of fiscal 2021), with most sales derived in the United States (72%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but roughly 20% of paid members carry business memberships. Food and sundries accounted for 40% of fiscal 2021 sales, with non-food merchandise 29%, warehouse ancillary and other businesses (such as fuel and pharmacy) nearly 17%, and fresh food 14%. Costco's warehouses average around 146,000 square feet
Read more on COST →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
